This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Reliable and on time translations and subtitling into Portuguese and English.
Account type
Freelance translator and/or interpreter, Verified site user
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliations
This person is not affiliated with any business or Blue Board record at ProZ.com.
Services
Translation
Expertise
Specializes in:
Finance (general)
Accounting
Economics
Advertising / Public Relations
Business/Commerce (general)
Tourism & Travel
Sports / Fitness / Recreation
Rates
English to Portuguese - Rates: 0.07 - 0.09 USD per word
English to Portuguese: Roche´s annual financial report General field: Bus/Financial Detailed field: Finance (general)
Source text - English The significant decline in overall sales was mainly due to regulatory and reimbursement uncertainty in the US, beginning in 2010, regarding the use of DRUG X for metastatic breast cancer. This led to lower sales in the US throughout 2011 and also affected uptake for breast cancer in certain European and Latin American markets.
The US market share in all other indications remained stable. Lower sales in Europe were due primarily to government austerity measures and price cuts, along with lower use for breast cancer. Market penetration in colorectal cancer remained stable despite increasing competition. Use of the medicine in lung cancer grew slightly in a number of EU countries. The approval by the EU in December 2011 of DRUG X for front-line treatment of newly diagnosed advanced ovarian cancer is expected to have a positive impact on sales in Europe from 2012 onwards.
Growth of 11% in the International region reflects strong uptake of DRUG X in its colorectal and lung cancer indications, led by Latin America (up 18%) and Asia–Pacific (up 34%), particularly in China following the launch for colorectal cancer in October 2010. Growth in Japan was driven by continued good uptake in non-small cell lung cancer. The new metastatic breast cancer indication, approved in Japan in September 2011, is also expected to contribute to future sales.
Translation - Portuguese A queda significativa no faturamento foi, principalmente, devido à regulamentação e a incerteza de reembolso nos EUA, começando em 2010, no que se refere ao uso da DROGA X para câncer de mama metastático. Tal fato levou à queda das vendas nos EUA em 2011 e também afetou o índice de uso da droga contra o câncer de mama em certos mercados europeus e latino-americanos.
A participação do mercado americano em todos os outros indicadores se manteve estável. O faturamento menor na Europa deveu-se, especialmente, às medidas de austeridade de governo e cortes nos preços, juntamente com o uso reduzido da droga para o câncer de mama. A penetração no mercado de câncer colorretal permaneceu estável, apesar da crescente concorrência. O uso do medicamento para câncer de pulmão cresceu ligeiramente em vários países da UE. É previsto um impacto positivo em vendas na Europa, a partir de 2012, com a aprovação pela UE em dezembro de 2011 da DROGA X, que é um tratamento de primeira linha para pacientes recém-diagnosticados com câncer de ovário avançado.
O crescimento de 11% na região Internacional reflete uma forte absorção da DROGA X em indicações para câncer de pulmão e de cólon, liderada pela América Latina (que subiu 18%) e Ásia-Pacífico (que cresceu 34%), especialmente na China, seguida do lançamento para câncer colorretal em Outubro de 2010. A expansão no Japão foi impulsionada pela contínua aceitação da droga para o câncer de pulmão de células não-pequenas. A nova indicação para câncer de mama metastático, aprovada no Japão em setembro de 2011, também espera contribuir para futuras vendas.
Portuguese to English: Annual report of XXXX, a Brazilian company General field: Bus/Financial Detailed field: Finance (general)
Source text - Portuguese (a) Considerações sobre riscos
(i) Risco de estrutura de capital
(ou risco financeiro)
Decorre da escolha entre capitai próprio (aportes de capita! e retenção de lucros) e capital de terceiros que as Empresas fazem para financiar suas operações. Para mitigar os riscos de liquidez e a otimização do custo médio ponderado do capital, as Empresas monitoram permanentemente os níveis de endividamento, de acordo eom os padrões de mercado e o cumprimento de índices (covenants) previstos em contratos de empréstimos e financiamentos.
(ii) Risco de crédito
A Companhia e sua controlada restringem a exposição a riscos de crédito associados a caixa e equivalentes de caixa, efetuando seus investimentos em instituições financeiras sólidas e com remuneração em títulos de curto prazo. Com relação ao contas a receber estão sujeitas a riscos de crédito em suas contas a receber de clientes, que de forma geral não tem garantias. Os procedimentos adotados para minimizar os riscos comerciais incluem a seletividade dos clientes, mediante uma adequada análise de crédito, estabelecimento de limites de venda e prazos curtos de vencimento dos títulos. As perdas estimadas com estes clientes são integralmente provisionadas.
(iii) Risco de taxa de juros
Decorre da possibilidade de a Companhia e sua controlada sofrerem ganhos ou perdas decorrentes de oscilações de taxas de juros incidentes sobre seus ativos e passivos financeiros. Visando à mitigação deste tipo de risco, a Companhia e sua controlada buscam diversificar a captação de recursos em termos de taxas prefixadas ou pos-fixadas. As taxas de juros sobre empréstimos, financiamentos estão mencionadas na Nota
A Companhia e suas controladas não possuem instrumentos derivativos para proteção do risco de flutuação da taxa de juros.
Translation - English a) Risk considerations
(i) Capital risk structure
(or financial risk)
It derives from the choice between equity (capital injection or retained earnings) and debt capital, used by companies to finance their operations. In order to mitigate liquidity risks and the optimization of the weighted average cost of capital, companies monitor permanently their leverage levels, according with the market standards and their covenants compliance, required in loans and financing contracts.
(ii) Credit Risk
The Company and its controlled subsidiary restrict their credit risk exposure associated with their cash and equivalents, making investments in solid institutions choosing short-term securities compensation. Regarding its accounts receivable, it is subject to credit risk when the Company's clients, in general, do not have guaranties. The procedures adopted to minimize commercial risks include the selection of clients, by means of an adequate credit analysis , establishment of sales limits, and short payment terms on their invoices. Estimated losses with these clients are fully provisioned.
(iii) Interest rates risk
It results from the possibility of the Company and its controlled subsidiary suffer profit or losses, derived from interest rates oscillations over their financial assets and liabilities. Targeting the mitigation of this type of risk, the Company and its controlled subsidiary seek the diversification when raising funds, mixing pre-fixed and post-fixed rates. Interest rates on loans and financing are mentioned in the Footnotes.
The Company and its controlled subsidiaries do not have derivative instruments to protect them from interest rates fluctuation risk.
More
Less
Translation education
Bachelor's degree - Federal University of Rio de Janeiro
Experience
Years of experience: 16. Registered at ProZ.com: Nov 2014.
Ana Guimarães has a Bachelor degree in Languages (Portuguese – English), a Master degree in Business Administration and an MBA in Corporate Finance. She has worked as an English teacher for three years, lived in the United States for four years, and since 2008, she has been in the Business/Finance field, writing and translating financial reports in her language pairs EN>PT>EN, being 7 of them as an employee of a multinational American company. In Jan 2015, she decided to become a freelancer translator, enjoying the flexibility of working hours, but still with responsibility, delivering all her jobs before the deadline.
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.
Portfolio